Vir Says Its Best-In-Class COVID-19 Antibody Profile Is Holding Up
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
You may also be interested in...
Other antibody treatments have shown efficacy in early-stage disease after faltering in hospitalized patients.
After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.
The dispute over a likely 60% reduction in supplies of AstraZeneca's COVID-19 vaccine shows no sign of resolution. Meanwhile, Lilly, Vir/GSK team up on COVID-19 antibody combination and Moderna negotiates sale of 100 million additional vaccine doses to US.